Neurology companies develop therapies, diagnostics and technologies that improve understanding and treatment of disorders affecting the brain, spinal cord and nervous system. The field addresses some of the most complex challenges in modern medicine.
This category includes companies working on:
Browse 114 UK neurology companies below.
DNA nanoprobes for intracellular biomarker profiling in neurodegeneration
Esya Labs is a precision biomarker company using patented DNA nanoprobes to measure ion signatures within intracellular organelles including endosomes and lysosomes. The technology enables ratiometric quantification of subcellular chemical states in living cells, with applications in early detection of…
siRNA gene therapies targeting root causes of ALS and frontotemporal dementia
Crucible Therapeutics Limited is a preclinical-stage biotechnology company developing siRNA-based gene therapies for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia caused by the C9orf72 gene mutation. Its therapeutic approach depletes the SRSF1 protein to suppress production of toxic dipeptide repeat…
Specialty pharmaceuticals for Parkinson's disease and related neurological conditions
Britannia Pharmaceuticals is a UK-based specialty pharmaceutical company developing and marketing treatments for Parkinson's disease and related conditions including psychosis. The company's product range includes apomorphine-based therapies available in multiple delivery formats, alongside clozapine-based treatment…
Small molecule protein degraders targeting oncology and CNS disease
Kesmalea Therapeutics is a biotechnology company developing oral small molecule therapeutics that modulate protein homeostasis through targeted protein degradation and stabilisation. The company's platform is designed to convert the potency of protein degrader approaches into orally bioavailable, CNS-penetrant small…
Small molecule remyelination therapeutics for neurological diseases
Pheno Therapeutics is a Scottish clinical-stage biotechnology company developing small molecule therapeutics that promote remyelination by boosting the function of oligodendrocytes in the central nervous system. Its lead programme PTD802, a selective GPR17 antagonist licensed from UCB, received MHRA clinical trial…
Antisense oligonucleotide therapies for TUBB4A-associated leukodystrophies
SynaptixBio is a biotechnology company developing antisense oligonucleotide therapies for severe inherited leukodystrophies. Its lead programme targets TUBB4A-associated hypomyelinating disorders, including hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC). The approach uses synthetic…
Phase 3 urcosimod therapy for neuropathic corneal pain
OKYO Pharma is a clinical-stage biopharmaceutical company developing topical therapies for neuropathic corneal pain and other ocular surface conditions. Its lead candidate, urcosimod (formerly OK-101), is a chemerin receptor agonist designed to modulate inflammation and corneal pain signalling. Phase 2a testing…
Digital cognitive assessment and CNS clinical trial software platform
Cambridge Cognition provides digital cognitive assessment and clinical trial technology for central nervous system drug development. Its validated computerised tests measure memory, attention and executive function across conditions including Alzheimer's disease and schizophrenia. The company also offers electronic…
Small molecule inhibitors targeting somatic expansion in neurodegeneration
LoQus23 Therapeutics is a biotechnology company developing oral small molecule inhibitors of DNA mismatch repair for the treatment of Huntington's disease and other triplet repeat expansion disorders. The company targets MutSβ, a protein complex whose aberrant activity drives somatic expansion and progressive…
Stem cell platform for precision psychiatry and drug discovery
MeOmics Precision Medicine is a biotechnology company developing a precision psychiatry platform that combines genomics, phenomics, and stem cell-based cellular assays to generate biomarkers for severe mental illness. Patient-derived neurons, stimulated via multi-electrode array recording, produce electrophysiological…
Targeted protein degradation platform for neurodegenerative disease
TRIMTECH Therapeutics is a biotechnology company developing small-molecule degraders that selectively remove disease-causing protein aggregates while preserving the functional, non-aggregated forms of the same proteins. The platform is built on research into the E3 ubiquitin ligase TRIM21, conducted over nearly two…
RBC derived nanoparticles for RNA delivery to brain and immune cells
Crane Biosciences is a biotechnology company developing a non-immunogenic RNA delivery platform based on nanoparticles derived from red blood cell membranes. By using the body's own cellular architecture as a delivery vehicle, the platform achieves substantially higher in vivo delivery efficiency to target tissues…
Tunable covalent chemistry platform for neurodegenerative disease
Dunad Therapeutics is a drug discovery biotech developing small molecule therapies for neurodegenerative diseases including ALS, frontotemporal dementia, and Parkinson's disease. Its platform combines tunable covalent chemistry with targeted protein degradation, using monovalent small molecules that form durable bonds…
Stem cell-derived exosome platform for targeted drug delivery
ReNeuron is a biotechnology company developing a stem cell-derived exosome platform for targeted therapeutic delivery. Founded on over two decades of stem cell science, including the world's first clinical trial of conditionally immortalised neural stem cell therapy for stroke disability, the company has pivoted to…
Autophagy-enhancing small molecule drugs for neurodegeneration and rare disease
Samsara Therapeutics is a drug discovery company developing first-in-class small molecule therapeutics that restore autophagy, the cellular process of degrading and recycling damaged proteins, which declines with age and is dysfunctional in multiple diseases. Its platform identifies and chemically optimises…
Next-generation targeted protein degradation therapeutics
Amphista Therapeutics is a Cambridge-based biopharmaceutical company developing next-generation targeted protein degradation medicines. Its proprietary platform generates bifunctional small molecule degraders that harness a broader range of the cell's protein-degrading machinery than existing approaches, enabling…
AI analysis of brain MRI for neurological diagnosis and prognosis
Ainostics is a medical artificial intelligence company developing software that analyses brain scans and clinical data to support the diagnosis and prognosis of neurological disorders. Its platform derives detailed measures of brain tissue structure from routine MRI and compares them with healthy populations to detect…
LNP-mRNA growth factor therapy to restore hearing loss
CamGene Therapeutics is a preclinical biotechnology company developing lipid nanoparticle-delivered mRNA medicines to treat hearing loss at its underlying cellular cause. Its lead approach uses an LNP-mRNA growth factor therapeutic designed to regenerate cochlear nerve cells and reduce inflammation, aiming to restore…
Affordable biochemicals, antibodies and reagents for life science research
Hello Bio is a Bristol-based manufacturer and supplier of biochemicals, antibodies, and reagents for life science research, offering validated tools at up to half the price of major suppliers. Products are manufactured in-house under ISO 9001 certification and span receptor ligands, enzyme inhibitors, ion channel…
Preclinical small-molecule therapeutics targeting a novel pathway in chronic pain
Sevenless Therapeutics is a preclinical biotechnology company developing small-molecule medicines for people with chronic pain that responds poorly to existing treatments. The company has identified a new target in pain signalling using computational and mathematical modelling approaches and is designing small…